Bladder Carcinoma Clinical Trial
Official title:
Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy
This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs. Gabapentin may reduce the amount of pain medicine required after surgery, improve pain after surgery, and/or reduce the length of hospital stay after surgery.
PRIMARY OBJECTIVES:
I. To assess if perioperative gabapentin will decrease post-operative analgesic requirements
within the first 48 hours after radical cystectomy (RC) in patients undergoing RC as measured
morphine equivalents.
SECONDARY OBJECTIVES:
I. To assess patient self-assessment of postoperative pain on Numeric Pain Scale (NPS) at 24
and 48 hours.
II. To assess time to return of bowel function (ROBF).
III. To assess length of stay (LOS) following RC.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive gabapentin orally (PO) thrice daily (TID) for 48 hours after surgery.
ARM II: Patients receive placebo PO TID for 48 hours after surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Active, not recruiting |
NCT05399004 -
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
|
||
Recruiting |
NCT03824691 -
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
|
Phase 2 | |
Recruiting |
NCT04502095 -
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
|
Phase 4 | |
Completed |
NCT03125226 -
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
|
N/A | |
Withdrawn |
NCT05564416 -
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
|
Phase 2 | |
Terminated |
NCT02169284 -
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
|
Phase 2 | |
Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
Active, not recruiting |
NCT02439060 -
PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit)
|
N/A | |
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Withdrawn |
NCT04054752 -
Vaccine Response With NT-I7
|
Phase 1 | |
Terminated |
NCT03549650 -
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
|
Phase 2 | |
Completed |
NCT00469066 -
Cone Beam CT Scanning in Lung and Bladder Cancer.
|
N/A | |
Active, not recruiting |
NCT03757949 -
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
|
Phase 3 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02408406 -
PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers
|
N/A | |
Recruiting |
NCT06109857 -
Bladder Bank (a Prospective Banking Study)
|
||
Terminated |
NCT02145390 -
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
|
N/A | |
Terminated |
NCT01245660 -
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
|
Phase 0 |